Welcome to our dedicated page for Evolus news (Ticker: $EOLS), a resource for investors and traders seeking the latest updates and insights on Evolus stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Evolus's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Evolus's position in the market.
News
Rhea-AI Summary
Evolus, Inc. (EOLS) reported positive financial results for Q4 2023 and full year 2023, with $0.8M cash generated from operating activities, a $3.7M non-GAAP operating loss for Q4, and $163.9M operating expenses. The company achieved a global net revenue record of $61.0M for Q4 and $202.1M for full year 2023, showing significant growth. Evolus updated its mid-term guidance, aiming for profitability in Q4 2024 and full year 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.87%
Tags
-
Rhea-AI Summary
Evolus, Inc. (EOLS) announces statistical superiority of Evolysse™/Estyme® Lift dermal filler over Restylane-L in improving nasolabial fold severity. The European Lift study met the primary endpoint of non-inferiority. The filler line will be launched globally in 2025, branded as Evolysse™ in the US and Estyme® in the UK and Europe. The study demonstrated statistical superiority of Evolysse™/Estyme® Lift at 3 and 6 months, positioning it as a versatile and high-volume filler. Safety profiles were similar with no serious adverse events reported.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
-
Rhea-AI Summary
Evolus, Inc. (EOLS) announces participation in upcoming investor conferences in March 2024. Management team to present at Leerink Partners Global Biopharma Conference and Barclays Global Healthcare Conference. Webcast available on Evolus website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.9%
Tags
Rhea-AI Summary
Evolus, Inc. (EOLS) announces the reporting of its fourth quarter and year-end 2023 financial results along with a business update on March 7, 2024. The company will host a conference call and live webcast to discuss the results, followed by a Q&A session.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.26%
Tags
-
Rhea-AI Summary
Evolus, Inc. grants 15,101 restricted stock units to 7 new non-executive employees under the 2023 Inducement Incentive Plan. The RSUs vest annually starting from February 7, 2024, subject to employment conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Evolus, Inc. (NASDAQ: EOLS) reported preliminary unaudited net revenue of $61 million for Q4 2023, a 40% increase from the prior year quarter, and $202 million for full-year 2023, a 36% increase from 2022. The company exceeded its 2023 net revenue guidance and expects 2024 net revenue to grow by 26-31%. The company also achieved significant milestones, including the expansion of its portfolio with the addition of late-stage dermal fillers expected to be launched in the U.S. and Europe in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.65%
Tags
Rhea-AI Summary
Evolus, Inc. (EOLS) granted non-qualified stock options and restricted stock units to six newly hired non-executive employees under its 2023 Inducement Incentive Plan. The options have an exercise price of $10.68 per share, a 10-year term, and vest over 4 years, while the RSUs vest 25% on each annual anniversary of the vesting commencement date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Evolus, Inc. (NASDAQ: EOLS) announced Nareg Sagherian as Vice President, Head of Global Investor Relations and Corporate Communications. Nareg brings extensive experience in capital markets, investor relations, corporate communications, and public policy from firms including FTI Consulting, Biotechnology Innovation Organization, and Booz Allen Hamilton. He will report to Sandra Beaver, Chief Financial Officer of Evolus.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.95%
Tags
-
Rhea-AI Summary
Evolus, Inc. (NASDAQ: EOLS) has entered into a distributor agreement with Symatese to expand its dermal filler footprint beyond the U.S. to include the United Kingdom and Europe. European regulatory approvals are anticipated in the second half of 2024, with commercialization under the brand name Estyme® fillers in 2025. This agreement doubles the company's total addressable international market to $1.8 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.63%
Tags
Rhea-AI Summary
Evolus, Inc. (NASDAQ: EOLS) granted 28,328 restricted stock units (RSUs) to 7 non-executive employees under the 2023 Inducement Incentive Plan, with vesting over 4 years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Evolus, Inc.
Nasdaq:EOLS
EOLS Rankings
EOLS Stock Data
850.88M
38.80M
13.05%
77.11%
7.56%
Medicinal and Botanical Manufacturing
Manufacturing
United States of America
NEWPORT BEACH
About EOLS
evolus, inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the united states. it offers jeuveau, a proprietary 900 kilodalton purified botulinum toxin type a formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. the company was founded in 2012 and is headquartered in newport beach, california.